vTv Therapeutics Inc. Class A Common Stock
Symbol: VTVT (NASDAQ)
21.41
▲ (2.98%) 0.620
Company Description:
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
Key Stats
- Today's Open: $21.1
- Today's High: $21.495
- Today's Low: $20.08
- Today's Volume: 815
- Yesterday Close: $20.79
- Yesterday High: $21.07
- Yesterday Low: $19.8265
- Yesterday Volume: 2.35K
- Last Min Volume: 4
- Last Min High: $21.41
- Last Min Low: $21.41
- Last Min VWAP: $21.41
Company Profile
- Name: vTv Therapeutics Inc. Class A Common Stock
- Website: https://www.vtvtherapeutics.com
- Listed Date: 2015-07-30
- Location: HIGH POINT, NC
- Market Status: Active
- CIK Number: 0001641489
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $54.96M
- Round Lot: 100
- Outstanding Shares: 2.62M
- Asset Type: CS
RECENT FILINGS FOR VTVT
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-03 | S-3 | View |
| 2025-09-25 | SCHEDULE 13D/A | View |
| 2025-09-25 | 4 | View |
| 2025-09-10 | 8-K | View |
| 2025-09-08 | SCHEDULE 13G | View |
| 2025-09-08 | SCHEDULE 13G | View |
| 2025-09-05 | 4 | View |
| 2025-09-05 | 4 | View |
| 2025-09-03 | SCHEDULE 13D/A | View |
| 2025-09-02 | 8-K | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 8-K | View |
| 2025-05-21 | 4 | View |
| 2025-05-21 | 3 | View |
Latest News on VTVT